Related to Convertible Note and Warrant Programmes established on December 22, 2017 between the FIT Biotech Oy ("Company") and Alpha Blue Ocean ("ABO") the Company's Board of Directors have resolved on September 19, 2018 to approve ABO's request relating to the funding programme to convert EUR 150,000 worth of Convertible Capital Notes into the Company's K shares.

Due to the conversion of the Convertible Capital Notes, the Company issues 375,000,000 new K shares in the Company to ABO with the conversion price of EUR 0.0004 per share and the share capital of the Company will be increased by EUR 150,000.00. The Board authorization is based on General Meeting April 12, 2018.

The Company holds 1,001,924,221 K shares.

The K shares will be admitted to trading on First North Finland on or about September 24, 2018.

About FIT Biotech FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.